SEARCH

SEARCH BY CITATION

References

  • 1
    Perinatal HIV Guidelines Working Group. Public health service task force recommendations for use of antiretroviral drugs in pregnant HIV-infected women for maternal health and interventions to reduce perinatal HIV transmission in the United States. Available at http://aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf (accessed 15 September 2009).
  • 2
    European AIDS Clinical Society. Guidelines: Clinical Management and Treatment of HIV Infected Adults in Europe Version 5-3, 2010. Available at http://www.europeanaidsclinicalsociety.org/guidelinespdf/1_Treatment_of_HIV_Infected_Adults.pdf (accessed 10 March 2010).
  • 3
    National Department of Health South Africa. National Antiretroviral Treatment Guideline, 2004. Available at http://hivinsite.ucsf.edu/doc/cr09-sf-01.doc (accessed 11 March 2010).
  • 4
    Anderson BL, Cu-Uvin S. Pregnancy and optimal care of HIV-infected patients. Clin Infect Dis 2009; 48: 449455.
  • 5
    Baylor MS, Johann-Liang R. Hepatotoxicity associated with nevirapine use. J Acquir Immune Defic Syndr 2004; 35: 538539.
  • 6
    Bouillon-Pichault M, Jullien V, Azria E et al. Population analysis of the pregnancy-related modifications in lopinavir pharmacokinetics and their possible consequences for dose adjustment. J Antimicrob Chemother 2009; 63: 12231232.
  • 7
    Mirochnick M, Best BM, Stek AM et al. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr 2008; 49: 485491.
  • 8
    Aweeka FT, Stek A, Best BM et al. Lopinavir protein binding in HIV-1-infected pregnant women. HIV Med 2010; 11: 232238.
  • 9
    Chandwani A, Shuter J. Lopinavir/ritonavir in the treatment of HIV-1 infection: a review. Ther Clin Risk Manag 2008; 4: 10231033.
  • 10
    Bongiovanni M, Cicconi P, Landonio S et al. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals. Int J Antimicrob Agents 2005; 26: 8891.
  • 11
    Molina JM, Andrade-Villanueva J, Echevarria J et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study. Lancet 2008; 372: 646655.
  • 12
    Johnson M, Grinsztejn B, Rodriguez C et al. 96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures. AIDS 2006; 20: 711718.
  • 13
    Acosta EP, Zorrilla C, Van Dyke R et al. Pharmacokinetics of saquinavir-SGC in HIV-infected pregnant women. HIV Clin Trials 2001; 2: 460465.
  • 14
    van Heeswijk RP, Khaliq Y, Gallicano KD et al. The pharmacokinetics of nelfinavir and M8 during pregnancy and post partum. Clin Pharmacol Ther 2004; 76: 588597.
  • 15
    Mirochnick M, Capparelli E. Pharmacokinetics of antiretrovirals in pregnant women. Clin Pharmacokinet 2004; 43: 10711087.
  • 16
    von Hentig N, Nisius G, Lennemann T et al. Pharmacokinetics, safety and efficacy of saquinavir/ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther 2008; 13: 10391046.
  • 17
    Kosel BW, Beckerman KP, Hayashi S, Homma M, Aweeka FT. Pharmacokinetics of nelfinavir and indinavir in HIV-1-infected pregnant women. AIDS 2003; 17: 11951199.
  • 18
    Ripamonti D, Cattaneo D, Maggiolo F et al. Atazanavir plus low-dose ritonavir in pregnancy: pharmacokinetics and placental transfer. AIDS 2007; 21: 24092415.
  • 19
    Agarwala S, Eley T, Filoramo D et al. Steady-state pharmacokinetics and inhibitory quotient of atazanavir with and without ritonavir in treatment naive HIV-infected patients. 7th International Workshop on Clinical Pharmacology of HIV Therapy, Lisbon, Portugal, 2006 [Abstract 85].
  • 20
    Wang X, Zhang J, Chung E et al. Effects of famotidine on the pharmacokinetics of atazanavir when given with ritonavir with or without tenofovir in HIV-infected subjects. 10th International Workshop on Clinical Pharmacology of HIV Therapy, Amsterdam, the Netherlands, 2009 [Abstract P_30].
  • 21
    Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events Version 1.0, December, 2004; Clarification August 2009. Available at http://rcc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS_AE_GradingTable_Clarification_August2009_Final.pdf (accessed 10 March 2010).
  • 22
    Acosta EP, Bardeguez A, Zorrilla CD et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004; 48: 430436.
  • 23
    Bryson YJ, Mirochnick M, Stek A et al. Pharmacokinetics and safety of nelfinavir when used in combination with zidovudine and lamivudine in HIV-infected pregnant women: Pediatric AIDS Clinical Trials Group (PACTG) Protocol 353. HIV Clin Trials 2008; 9: 115125.
  • 24
    Cressey TR, Van Dyke R, Jourdain G et al. Early postpartum pharmacokinetics of lopinavir initiated intrapartum in Thai women. Antimicrob Agents Chemother 2009; 53: 21892191.
  • 25
    Mirochnick M, Dorenbaum A, Holland D et al. Concentrations of protease inhibitors in cord blood after in utero exposure. Pediatr Infect Dis J 2002; 21: 835838.
  • 26
    Eley T, Child M, Wang Y et al. The steady state pharmacokinetics (PK) of atazanavir/ritonavir (ATV/RTV) during pregnancy in HIV+ women. 47th Annual Meeting of the Infectious Diseases Society of America. Philadelphia, PA, USA, 2009 [Abstract 279].
  • 27
    Waffarn F, Carlisle S, Pena I, Hodgman JE, Bonham D. Fetal exposure to maternal hyperbilirubinemia. Neonatal course and outcome. Am J Dis Child 1982; 136: 416417.
  • 28
    Cotton DB, Brock BJ, Schifrin BS. Cirrhosis and fetal hyperbilirubinemia. Obstet Gynecol 1981; 57: 25S27S.
  • 29
    Dubey AP, Garg A, Bhatia BD. Fetal exposure to maternal hyperbilirubinemia. Indian Pediatr 1983; 20: 527528.
  • 30
    Lipsitz PJ, Flaxman LM, Tartow LR, Malek BK. Maternal hyperbilirubinemia and the newborn. Am J Dis Child 1973; 126: 525527.
  • 31
    Malan DR, Krantz E, David N, Wirtz V, Hammond J, McGrath D. Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients. J Acquir Immune Defic Syndr 2008; 47: 161167.
  • 32
    American Academy of Pediatrics. Practice parameter: management of hyperbilirubinemia in the healthy term newborn. American Academy of Pediatrics. Provisional Committee for Quality Improvement and Subcommittee on Hyperbilirubinemia. Pediatrics 1994; 94: 558565.
  • 33
    Vreman HJ, Wong RJ, Stevenson DK. Phototherapy: current methods and future directions. Semin Perinatol 2004; 28: 326333.
  • 34
    Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services, January 2011. Available at www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf (accessed 31 March 2011).
  • 35
    Vincent I, Piketty C, Gerard L et al. Pharmacokinetic parameters of atazanavir/ritonavir when combined to tenofovir in HIV-infected patients with multiple treatment failures: a substudy of puzzle2-ANRS 107 trial. 4th International Workshop on Clinical Pharmacology of HIV Therapy, Cannes, France, 2003 [Abstract 62].
  • 36
    Zhu L, Laio S, Child M et al. Pharmacokinetics and inhibitory quotient of atazanavir/ritonavir 300/100 mg once daily compared to lopinavir/ritonavir 400/100 mg twice daily, each in combination with fixed dose tenofovir-emtricitabine once daily, are supportive of 48 week efficacy and safety in HIV-1 infected, treatment-naive subjects. 9th International Workshop on Clinical Pharmacology of HIV Therapy, 2008 [Abstract O23].
  • 37
    Mirochnick M, Stek A, Capparelli E et al. Atazanavir pharmacokinetics with and without tenofovir during pregnancy. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada, February 2009 [Abstract T-140].
  • 38
    von Hentig N, Babacan E, Lennemann T et al. The steady-state pharmacokinetics of atazanavir/ritonavir in HIV-1-infected adult outpatients is not affected by gender-related co-factors. J Antimicrob Chemother 2008; 62: 579582.
  • 39
    McGrath D, Uy J, Yang R, Thiry A, Mancini M, Absalson J. Efficacy and safety by racial group in ARV-naive subjects treated with atazanavir/ritonavir or lopinavir/ritonavir: 48-weeks results for the CASTLE study (AI424138). XVII International AIDS Conference. Mexico City, Mexico, 2008 [Abstract TUPE 0058].